Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Synergy Flaunts Constipation Data From Linzess Challenger

Executive Summary

Synergy Pharmaceuticals, which is waiting on a decision from the US FDA on its constipation drug plecanatide, provided additional data from two pivotal Phase III trials at Digestive Disease Week (DDW) in San Diego recently. The product will go up against Linzess, which is marketed by Allergan and Ironwood Pharmaceuticals, and is expected to compete on its better side effect profile.

You may also be interested in...



Keeping Track: Trulance Is First Novel Drug Of 2017; Vantrela ER Is Year's Second Abuse-Deterrent Opioid

The latest drug development news and highlights from our FDA Performance Tracker.

Advantage For Synergy’s Plecanatide Over Rival Linzess Holds Up In IBS-C

Plecanatide met the primary endpoint in first Phase III trial in irritable bowel syndrome with constipation, with less incidence of diarrhea than seen in Linzess trials. Synergy is awaiting approval in chronic idiopathic constipation and appears on pace to file an sNDA in IBS-C during the first quarter.

Synergy rockets on Phase III constipation data

Positive topline results from the first of two pivotal Phase III trials of Synergy Pharmaceuticals' chronic idiopathic constipation drug plecanatide have sent the company's share price soaring.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC065256

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel